(Q37579222)

21 August 2017

1 reference

title

New generation azole antifungals in clinical investigation (English)

1 reference

21 August 2017

Corrado Girmenia

1

1 reference

PubMed ID

19678798

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Investigational Drugs

21 August 2017

1 reference

21 August 2017

18

1 reference

21 August 2017

9

1 reference

21 August 2017

1279-1295

1 reference

Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

The place for itraconazole in treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

New and emerging treatments for fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Clinical pharmacokinetics of systemically administered antimycotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Update on azole antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in h

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Voriconazole : a review of its use in the management of invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Pharmacokinetic/pharmacodynamic profile of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Posaconazole: an oral triazole with an extended spectrum of activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Antifungal therapeutic drug monitoring: established and emerging indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Posaconazole: a broad-spectrum triazole antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

The safety of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Antifungal drug resistance: limited data, dramatic impact?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Update on antifungal drug resistance mechanisms of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Rapid detection of triazole antifungal resistance in Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In Vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro antifungal activity of BMS-207147 and itraconazole against yeast strains that are non-susceptible to fluconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro susceptibility testing of Geotrichum capitatum: comparison of the E-test, disk diffusion, and Sensititre colorimetric methods with the NCCLS M27-A2 broth microdilution reference method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Molecular identification and susceptibility of Trichosporon species isolated from clinical specimens in Qatar: isolation of Trichosporon dohaense Taj-Aldeen, Meis & Boekhout sp. nov

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro activities of four novel triazoles against Scedosporium spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Antifungal susceptibilities of the species of the Pseudallescheria boydii complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro interactions of approved and novel drugs against Paecilomyces spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Posaconazole as salvage therapy for zygomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Efficacy of albaconazole (UR-9825) in treatment of disseminated Scedosporium prolificans infection in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

The enzymatic basis of drug-drug interactions with systemic triazole antifungals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543780903176407

10.1517/13543780903176407

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference

PubMed ID

19678798